Drug
Cedazuridine clinical trials
- studies test it
- 13
- open now
- 8
- in phase 3
- 2
- first study started
- 2020
Keep track of what changes. Save the cedazuridine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 8
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 8
Astex Pharmaceuticals, Inc. (2) · Rutgers, The State University of New Jersey (2) · Otsuka Australia Pharmaceutical Pty Ltd (1) · National Cancer Institute (NCI) (1) · Taiho Oncology, Inc. (1) · M.D. Anderson Cancer Center (1) · PETHEMA Foundation (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Decitabine (11) · Venetoclax (4) · Azacitidine (2) · Hydroxychloroquine (1) · Olutasidenib (1) · Ivosidenib (1) · Avapritinib (1) · Defactinib (1)
Studies
Open first, then newest update. How each study uses cedazuridine is read from its arms, and is right about nine times in ten.
Testing it · 13
- Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingPhase 2National Cancer Institute (NCI)NCT05960773Written as Decitabine/cedazuridine
- Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLNot yet recruitingPhase 2Rutgers, The State University of New JerseyNCT07867626Written as decitabine/cedazuridine
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingPhase 2/3Taiho Oncology, Inc.NCT04256317Written as Cedazuridine
- Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06445959Written as Decitabine/cedazuridine
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- Hydrochloroquinine & Decitabine With Venetoclax in AMLNot yet recruitingPhase 1Rutgers, The State University of New JerseyNCT07814339Written as Oral Decitabine/cedazuridine
- Avapritinib With Decitabine in Patients With SM-AHNRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06327685Written as Decitabine/Cedazuridine
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingPhase 1Clinical Hub for Interventional Research (CHOIR)NCT05636514Written as Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantTerminatedPhase 2Sanjay MohanNCT05799079Written as Cedazuridine
- A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingPhase 3Otsuka Australia Pharmaceutical Pty LtdNCT05883956Written as Oral decitabine/cedazuridine
- A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedPhase 2Astex Pharmaceuticals, Inc.NCT05835011Written as Decitabine/Cedazuridine
- Thorough QT Assessment of Cedazuridine in Healthy SubjectsCompletedPhase 1Astex Pharmaceuticals, Inc.NCT04953923Written as Cedazuridine
- A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesWithdrawnPhase 2TakedaNCT04985656Written as Cedazuridine
Given in every arm · 3 — cedazuridine is usual care beside what is tested
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)TerminatedPhase 1Taiho Oncology, Inc.NCT05403450Written as Decitabine + Cedazuridine
- Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid TumorsActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03875287Written as Cedazuridine
- Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingPhase 1Jacqueline Garcia, MDNCT03613532Written as Decitabine/cedazuridine
Codes
What other systems call cedazuridine · ClinicalTrials.gg INT001153
- MeSH (NLM) C000633944cedazuridineOne source NLM
- UNII (FDA) 39IS23Q1EWCEDAZURIDINEConfirmed FDA, NLM
- RxNorm 2384449One source FDA
- NCI Thesaurus C164146CedazuridineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633944 | cedazuridine | One source NLM |
| UNII (FDA) | 39IS23Q1EW | CEDAZURIDINE | Confirmed FDA, NLM |
| RxNorm | 2384449 | — | One source FDA |
| NCI Thesaurus | C164146 | Cedazuridine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.